S-1/A: cbdMD Registers 1.7M Shares for Resale, Details Capital Structure & Regulatory Threats

cbdMD, Inc. filed an S-1/A to register 1.7 million common shares for resale by Series B Preferred Stock holders, while detailing recent capital raises, reduced operating losses, and significant regulatory challenges.

Summary

• Registration of up to 1,700,000 common shares for resale by existing Series B Convertible Preferred Stock selling shareholders.
• The company will not receive any proceeds from the sale of these shares by the Selling Shareholders.
• Reduced GAAP operating loss from $3.3 million in fiscal 2024 to $2.1 million in fiscal 2025.
• Successfully converted Series A Convertible Preferred Stock and accrued dividends into approximately 91% of outstanding common stock in April 2025, regaining NYSE American listing compliance.
• Launched the Oasis hemp-derived THC beverage brand, which is growing but currently an earnings drag.
• Identified nearly $200,000 in corporate overhead savings to be implemented in early fiscal 2026.
• Entered into an Equity Line of Credit (ELOC) agreement on December 15, 2025, for up to $20 million of common stock.
• Issued 1,000,000 shares of Series C Convertible Preferred Stock for $2,250,000 gross proceeds to two institutional investors on December 18, 2025.
• Series B Preferred Stock, issued on September 29, 2025, generated $1,700,000 in gross proceeds for working capital and general corporate purposes.

Sentiment

Score: 3

Explanation: While the company reduced its operating loss and regained NYSE compliance, the significant regulatory threats, the 'going concern' warning from auditors, and the substantial potential for dilution from recent and planned capital raises create a highly cautious outlook. The growth of the Oasis brand is positive but offset by its current 'earnings drag' status.

Positives

• Reduced GAAP operating loss from $3.3 million in fiscal 2024 to $2.1 million in fiscal 2025, indicating improved operational efficiency.
• Successfully cleaned up the capital structure by converting Series A Preferred Stock, regaining compliance with NYSE American listing standards, and removing non-compliance status.
• The Oasis brand is showing sequential and year-over-year revenue growth and expanding distribution across the Southeast and other states.
• Identified nearly $200,000 in corporate overhead savings to be implemented in early fiscal 2026.
• Secured new financing through an ELOC agreement for up to $20 million and a Series C Preferred Stock issuance for $2,250,000.

Negatives

• The Oasis brand, while growing, is currently an "earnings drag" on the company due to investment in scaling.
• Federal regulatory action in November 2025 poses a "significant threat" to the industry and the company's revenue bases.
• The auditor's report includes an explanatory paragraph regarding the Company's ability to continue as a going concern.
• The resale of 1,700,000 common shares by selling shareholders will not generate any proceeds for the company.
• Significant potential for dilution from the conversion of Series B and Series C Preferred Stock, as well as outstanding options, restricted stock awards, and warrants.

Risks

• Investing in the company's securities involves a high degree of risk.
• Failure to satisfy NYSE American continued listing standards could result in delisting, leading to a lack of trading market, reduced liquidity, and inability to obtain additional financing.
• The company has broad discretion over the use of proceeds from Series B Preferred Stock sales, which may not yield significant returns or align with investor expectations.
• The issuance of shares upon exercise of outstanding options, restricted stock awards, warrants, or the conversion of Series B and Series C Preferred Stock may cause immediate and substantial dilution to existing shareholders.
• Federal regulatory action in November 2025 poses a significant threat to the hemp industry and the company's revenue bases.
• The company's independent registered public accounting firm included an explanatory paragraph on the company's ability to continue as a going concern in their audit report.

Future Outlook

The company anticipates continued momentum in its direct-to-consumer and wholesale businesses, with additional Oasis distribution expected in the first quarter of fiscal 2026. Management is implementing nearly $200,000 in corporate overhead savings in early 2026. However, federal regulatory actions from November 2025 pose a significant threat to future revenue bases.

Management Comments

• "Managements efforts to drive shareholder value during 2025 were focused in two areas: (i) deliver positive earnings through a combination of optimizing our product portfolio, rationalizing our cost structure, and growing revenue and (ii) simplifying our capital structure."
• "During fiscal 2025, we made progress on strengthening the business. We were able to essentially maintain our revenue base and we continued to reduce our GAAP operating loss from a $3.3 million loss during fiscal 2024 to $2.1 million during fiscal 2025."
• "This vote [Series A conversion] was critical to regaining compliance with NYSE American continued listing standards and maintaining our NYSE American listing as well as make the Company more attractive for merger and acquisition activity."
• "cbdMD believes trends from late 2025 are continuing in the first quarter of 2026."
• "To date, Oasis has been a P&L earnings drag on the Company as we invest in a scaling, high-growth category."

Industry Context

The filing highlights a challenging regulatory environment for the hemp-derived product industry, with a "notable uptick in both state and federal regulatory activity" in calendar 2025. Federal action in November 2025 is specifically cited as a "significant threat." This suggests increasing scrutiny and potential headwinds for companies operating in the CBD and hemp-derived THC beverage sectors, which could impact market growth and operational stability across the industry.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• The company reimbursed the Selling Shareholders $200,000 for costs and expenses incurred in connection with the private placement transactions.

Stakeholder Impact

• Shareholders: Potential for significant dilution due to the conversion of Series B and Series C Preferred Stock, as well as outstanding options and warrants. Existing shareholders' economic and voting interests will be diluted.
• Investors (new): High degree of risk due to regulatory threats, going concern warning, and potential for dilution.
• Management/Employees: CEO's salary increased, and new equity awards granted, potentially boosting morale and retention.
• Creditors: The "going concern" warning from auditors could raise concerns about the company's long-term financial viability.

Next Steps

• The registration statement needs to become effective for the Selling Shareholders to resell their shares.
• Implementation of nearly $200,000 in corporate overhead savings during early fiscal 2026.
• Continued investment and scaling of the Oasis brand, with efforts to reduce overhead expenses and add sales staff.
• Shareholder approval is required for the 445,000 shares of unvested restricted common stock granted under the 2025 Equity Incentive Plan.
• The company will file a further amendment to delay the effective date of the registration statement until it specifically states it shall become effective or the SEC determines.

Key Dates

Recommendation

The filing reveals several critical concerns that warrant a 'sell' recommendation. The auditor's 'going concern' warning is a severe red flag, indicating substantial doubt about the company's ability to continue operations. Furthermore, the explicit mention of 'significant threat' from federal regulatory action in November 2025 points to severe industry-specific headwinds that could materially impact revenue. While the company has reduced operating losses and regained NYSE compliance, these positives are overshadowed by the high potential for dilution from multiple recent and planned capital raises (Series B, Series C, ELOC) and the fact that the current S-1/A is for resale by existing shareholders, meaning no new capital for the company from this specific offering. The Oasis brand, a growth area, is also noted as an 'earnings drag.' These factors collectively suggest a highly precarious financial position and significant downside risk for investors.

Keywords

cbdMD, YCBD, SEC Filing, S-1/A, Common Stock Resale, Preferred Stock, Series B Preferred, Series C Preferred, Capital Raise, Dilution, Hemp Industry, CBD, Cannabidiol, Oasis Beverage, Regulatory Risk, NYSE American, Going Concern, Financial Performance, Operating Loss, Corporate Governance